Clinical Trials Related to Multiple Myeloma

Related studies linked through entity extraction aliases.

Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Status: RECRUITING
Phase: PHASE1

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Status: RECRUITING
Phase: PHASE2

Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment

Status: RECRUITING
Phase: NA

Proteomic Analysis of Patients Undergoing Bariatric Surgery

Status: NOT_YET_RECRUITING
Phase: NA

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

Status: RECRUITING
Phase: N/A

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Status: RECRUITING
Phase: PHASE1

Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Status: RECRUITING
Phase: PHASE1/PHASE2

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Status: RECRUITING
Phase: PHASE1

Multi-center Screening for Serum M Protein

Status: NOT_YET_RECRUITING
Phase: N/A

SIL as Maintenance Therapy in Multiple Myeloma

Status: NOT_YET_RECRUITING
Phase: PHASE2

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

Status: NOT_YET_RECRUITING
Phase: PHASE3

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Status: RECRUITING
Phase: EARLY_PHASE1

Elranatamab in Relapsed/Refractory Multiple Myeloma

Status: RECRUITING
Phase: PHASE2

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Status: NOT_YET_RECRUITING
Phase: PHASE1

A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

Status: RECRUITING
Phase: PHASE1

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

Status: RECRUITING
Phase: N/A

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Status: WITHDRAWN
Phase: PHASE1

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Status: RECRUITING
Phase: NA